Publicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (10)

2022

  1. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

    European Thyroid Journal, Vol. 11, Núm. 5

2018

  1. Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii476

2013

  1. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study

    BMC Cancer, Vol. 13

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

1995

  1. Chemotherapy and radiotherapy in locally advanced cervical cancer

    Acta Oncologica, Vol. 34, Núm. 7, pp. 941-944

  2. EXPERIENCIA A 10 ANOS CON QUIMIOTERAPIA Y CIRUGIA EN LA SEGUNDA LAPAROTOMIA EN CANCER DE OVARIO AVANZADO

    Medicina Clinica, Vol. 104, Núm. 5, pp. 165-169

1994

  1. Lobular carcinoma in situ of the breast

    Medicina clínica, Vol. 103, Núm. 14, pp. 553-556

1992

  1. CASO CLINICO: USO DE GM-CSF EN AUTOTRASPLANTE DE MEDULA OSEA

    Farmacia Hospitalaria, Vol. 16, Núm. 3, pp. 206-213